Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Vertex Pharmaceuticals
Company

Vertex Pharmaceuticals

Tracked across 2 events · 18 articles · First seen Feb 03, 2026 · Last active Mar 10, 2026

Sentiment
65
Attention
8
Events
2
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (2)
2 50
Business
WuXi Biologics, Vertex Pharmaceuticals TCE Agreement
Vertex Pharmaceuticals Incorporated gained exclusive global rights to develop and commercialize an innovative trispecific T-cell Engager (TCE) from WuXi Biologics. This agreement provides Vertex with a new tool to accelerate its efforts in advancing medicines for serious diseases, particularly B-cell mediated autoimmune diseases.
Feb 03, 2026 · 7 articles
8 80
International
Middle East Conflict Fuels Oil Volatility
Vertex Pharmaceuticals saw a significant stock increase after reporting positive trial results for its kidney disease treatment, demonstrating company-specific news can still drive gains amidst broader market concerns.
Mar 10, 2026 · 11 articles
Relationships (2)
WuXi Biologics partner ↔ Vertex Pharmaceuticals WuXi Biologics and Vertex Pharmaceuticals Incorporated entered a licensing and r
Mark Bunnage Chief Scientific Officer ↔ Vertex Pharmaceuticals Mark Bunnage is the Chief Scientific Officer at Vertex Pharmaceuticals Incorpora
NEWSDESK
Track Vertex Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.